Drug clinical trials on high-grade gliomas: challenges and hopes

Mengqian Huang; Shenglan Li; Parker Li; Zhuang Kang; Botao Zhang; Wenbin Li

doi:10.20892/j.issn.2095-3941.2023.0364

Cancer Biology & Medicine 2023, 20(12): 947-954 https://doi.org/10.20892/j.issn.2095-3941.2023.0364

Editorial |

Open Access | Issue | Published: 05 February 2024

Drug clinical trials on high-grade gliomas: challenges and hopes

Show Author's Information Hide Author's Information Mengqian Huang^¹, Shenglan Li^¹, Parker Li^², Zhuang Kang^¹, Botao Zhang^¹, Wenbin Li^¹

(

)

Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

Clinical Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Cite this article:

Huang M, Li S, Li P, et al. Drug clinical trials on high-grade gliomas: challenges and hopes. Cancer Biology & Medicine, 2023, 20(12): 947-954. https://doi.org/10.20892/j.issn.2095-3941.2023.0364

Download citation

EndNote(RIS)

BibTeX

Views

Downloads

Citations

Crossref

WoS

Scopus

N/A

CSCD

Full text About this article

Full text

Outline

About this article

Drug clinical trials on high-grade gliomas: challenges and hopes

Show Author's information Hide Author's Information Mengqian Huang^¹, Shenglan Li^¹, Parker Li^², Zhuang Kang^¹, Botao Zhang^¹, Wenbin Li^¹

(

)

Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China

Clinical Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

References(36)

Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020; 70: 299-312.

DOI Google Scholar

van Tellingen O, Yetkin-Arik B, de Gooijer M, Wesseling P, Wurdinger T, de Vries HE. Overcoming the blood–brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015; 19: 1-12.

DOI Google Scholar

Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017; 377: 1954-63.

DOI Google Scholar

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, et al. Phase Ⅱ trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13: 1253-9.

DOI Google Scholar

de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O’Brien B, et al. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020; 22: 539-49.

DOI Google Scholar

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018; 379: 722-30.

DOI Google Scholar

Duerinck J, Schwarze JK, Awada G, Tijtgat J, Vaeyens F, Bertels C, et al. Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase Ⅰ clinical trial. J Immunother Cancer. 2021; 9: e002296.

DOI Google Scholar

Friedman GK, Johnston JM, Bag AK, Bernstock JD, Li R, Aban I, et al. Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. N Engl J Med. 2021; 384: 1613-22.

DOI Google Scholar

Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995; 1: 938-43.

DOI Google Scholar

Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015; 33: 2780-8.

DOI Google Scholar

Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A. 2013; 110: 12006-11.

DOI Google Scholar

Todo T, Ino Y, Ohtsu H, Shibahara J, Tanaka M. A phase Ⅰ/Ⅱ study of triple-mutated oncolytic herpes virus G47Δ in patients with progressive glioblastoma. Nat Commun. 2022; 13: 4119.

DOI Google Scholar

Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003; 95: 652-60.

DOI Google Scholar

Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, et al. Phase Ⅰ study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018; 36: 1419-27.

DOI Google Scholar

Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent gliobla stoma: a phase 1/2 trial. Nat Med. 2023; 29: 1370-8.

DOI Google Scholar

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017; 170: 1109-19.e10.

DOI Google Scholar

Zhao Q, Zhang W, Ning Z, Zhuang X, Lu H, Liang J, et al. A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity. PLoS One. 2014; 9: e93103.

DOI Google Scholar

Zhang B, Huang J, Tang J, Hu S, Luo S, Luo Z, et al. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase Ⅰ/Ⅱ clinical trial. J Immunother Cancer. 2021; 9: e002224.

DOI Google Scholar

De Vleeschouwer S, Fieuws S, Rutkowski S, van Calenbergh F, van Loon J, Goffin J, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008; 14: 3098-104.

DOI Google Scholar

Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2023; 9: 112-21.

DOI Google Scholar

Wu J, Chen H, Li H, Tang Y, Yang L, Cao S, et al. Antidepressant potential of chlorogenic acid-enriched extract from eucommia ulmoides oliver bark with neuron protection and promotion of serotonin release through enhancing synapsin Ⅰ expression. Molecules. 2016; 21: 260.

DOI Google Scholar

Xue N, Zhou Q, Ji M, Jin J, Lai F, Chen J, et al. Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype. Sci Rep. 2017; 7: 39011.

DOI Google Scholar

Kang Z, Li S, Kang X, Deng J, Yang H, Chen F, et al. Phase Ⅰ study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up. Cancer Biol Med. 2023; 20: 465-76.

DOI Google Scholar

Danciu OC, Holdhoff M, Peterson RA, Fischer JH, Liu LC, Wang H, et al. Phase Ⅰ study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies. Br J Cancer. 2023; 128: 783-92.

DOI Google Scholar

Holdhoff M, Nicholas MK, Peterson RA, Maraka S, Liu LC, Fischer JH, et al. Phase Ⅰ dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas. Neurooncol Adv. 2023; 5: vdad087.

DOI Google Scholar

DeWire M, Fuller C, Hummel TR, Chow LML, Salloum R, de Blank P, et al. A phase Ⅰ/Ⅱ study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). J Neuro Oncol. 2020; 149: 511-22.

DOI Google Scholar

Olmez I, Zhang Y, Manigat L, Benamar M, Brenneman B, Nakano I, et al. Combined c-Met/Trk inhibition overcomes resistance to CDK4/6 inhibitors in glioblastoma. Cancer Res. 2018; 78: 4360-9.

DOI Google Scholar

Liu X, Chen X, Shi L, Shan Q, Cao Q, Yue C, et al. The thirdgeneration EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma. J Exp Clin Cancer Res. 2019; 38: 219.

DOI Google Scholar

Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2019; 20: 110-9.

DOI Google Scholar

Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380: 358-65.

DOI Google Scholar

Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos F, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022; 23: 53-64.

DOI Google Scholar

Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, et al. Vorasidenib and ivosidenib in IDH1-mutant lowgrade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2023; 29: 615-22.

DOI Google Scholar

Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, et al. Vorasidenib in IDH1- or IDH2-mutant lowgrade glioma. N Engl J Med. 2023; 389: 589-601.

DOI Google Scholar

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013; 155: 462-77.

DOI Google Scholar

Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, et al. Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: an open-label, multicenter, multi-arm, phase Ⅱ trial. J Clin Oncol. 2019; 37: 741-50.

DOI Google Scholar

Rosenthal M, Clement PM, Campone M, Gil-Gil MJ, DeGroot J, Chinot O, et al. Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ⅰb/Ⅱ, open-label, multicentre, randomised study. ESMO open. 2020; 5: e000672.

DOI Google Scholar

About this article

Publication history

Rights and permissions

Publication history

Received: 18 September 2023

Accepted: 24 November 2023

Published: 05 February 2024

Issue date: December 2023

Copyright

Rights and permissions

Creative Commons Attribution-NonCommercial 4.0 International License